Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen.
Horm Res Paediatr
; 81(3): 204-10, 2014.
Article
em En
| MEDLINE
| ID: mdl-24356182
ABSTRACT
BACKGROUND/AIMS:
Intravenous bisphosphonate therapy is the mainstay of medical treatment in osteogenesis imperfecta (OI) and has been shown to increase bone mass, decrease bone pain, improve mobility, and reduce the incidence of fractures. Sclerotic metaphyseal lines parallel to the growth plate are seen on long bone radiographs following cyclical intravenous therapy. These areas create stress risers within the bone that may act as foci for subsequent fractures as exemplified in this clinical case.METHODS:
An 8-year-old girl with OI sustained a distal radial fracture following 3 years of treatment with 6-monthly intravenous zoledronate. Her diagnosis, response to treatment, and subsequent fracture at a sclerotic metaphyseal line is described.RESULTS:
Peripheral quantitative computer tomography was used to characterise the presence of multiple stress risers at the distal forearm. Trabecular bone mineral density fluctuated from 34 to 126% compared to neighbouring 2-mm regions.CONCLUSION:
There remain many unanswered questions about optimal bisphosphonate treatment regimens in children with OI. The formation of stress risers following intravenous bisphosphonate treatment raises the hypothesis that a more frequent and low-dose bisphosphonate regimen would provide more uniform dosing of bone in the growing child and reduce the likelihood of fractures compared to current treatment practices.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Osteogênese Imperfeita
/
Fraturas do Rádio
/
Densidade Óssea
/
Difosfonatos
/
Conservadores da Densidade Óssea
/
Imidazóis
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article